Literature DB >> 10565831

Intracisternal nor-binaltorphimine distinguishes central and peripheral kappa-opioid antinociception in rhesus monkeys.

M C Ko1, M D Johnson, E R Butelman, K J Willmont, H I Mosberg, J H Woods.   

Abstract

Systemic administration of nor-binaltorphimine (nor-BNI) produces a long-lasting kappa-opioid receptor (kappaOR) antagonism and has kappa(1)-selectivity in nonhuman primates. The aim of this study was to establish the pharmacological basis of central kappaOR antagonism in rhesus monkeys (Macaca mulatta). After intracisternal (i.c.) administration of small doses of nor-BNI, the duration and selectivity of nor-BNI antagonism were evaluated against two kappaOR agonists, (trans)-3, 4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide (U50,488) and bremazocine. Thermal antinociception was measured in the warm water (50 degrees C) tail-withdrawal assay and sedation was evaluated by observers blind to treatment conditions. Following i.c. pretreatment with 0.32 mg nor-BNI, a 5- to 10-fold rightward shift of the U50,488 baseline dose-effect curve was observed in antinociception. In contrast, this dose of nor-BNI only produced an insignificant 2-fold shift against bremazocine. Pretreatment with a smaller dose (0.032 mg) of nor-BNI produced a 3-fold shift of U50, 488, which lasted for 7 days, but failed to alter the potency of bremazocine. This differential antagonism profile of i.c. nor-BNI also was observed in sedation ratings. In addition, the centrally effective dose of nor-BNI (0.32 mg), when administered s.c. in the back, did not antagonize either U50,488- or bremazocine-induced antinociception and sedation. After i.c. pretreatment with the same dose, nor-BNI also did not antagonize the peripherally mediated effect of U50,488 against capsaicin-induced thermal nociception in the tail. These results indicate that i.c. nor-BNI produces central kappaOR antagonism and support the notion of two functional kappaOR subtypes in the central nervous system. Moreover, it provides a valuable pharmacological basis for further characterizing different sources of kappaOR-mediated effects, namely, from central or peripheral nervous system receptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10565831      PMCID: PMC2939326     

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  42 in total

1.  Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys.

Authors:  M C Ko; E R Butelman; J R Traynor; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

Review 2.  Mu-, delta-, kappa-opioid receptors and their subtypes. A critical review with emphasis on radioligand binding experiments.

Authors:  C J Fowler; G L Fraser
Journal:  Neurochem Int       Date:  1994-05       Impact factor: 3.921

Review 3.  Discriminative stimulus and subjective effects of opioids with mu and kappa activity: data from laboratory animals and human subjects.

Authors:  L A Dykstra; K L Preston; G E Bigelow
Journal:  Psychopharmacology (Berl)       Date:  1997-03       Impact factor: 4.530

4.  Activation of peripheral kappa opioid receptors inhibits capsaicin-induced thermal nociception in rhesus monkeys.

Authors:  M C Ko; E R Butelman; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1999-04       Impact factor: 4.030

5.  Bremazocine is an agonist at kappa-opioid receptors and an antagonist at mu-opioid receptors in the guinea-pig myenteric plexus.

Authors:  A D Corbett; H W Kosterlitz
Journal:  Br J Pharmacol       Date:  1986-09       Impact factor: 8.739

6.  Naloxone benzylhydrazone is a µ-selective opioid antagonist without kappa agonist effects in rhesus monkeys.

Authors:  C.P. France; J.H. Woods
Journal:  Behav Pharmacol       Date:  1992-04       Impact factor: 2.293

7.  Opioid kappa receptors and the secretion of prolactin (PRL) and growth hormone (GH) in the rat. I. Effects of opioid kappa receptor agonists bremazocine and U-50,488 on secretion of PRL and GH: comparison with morphine.

Authors:  L Krulich; J I Koenig; S Conway; S M McCann; M A Mayfield
Journal:  Neuroendocrinology       Date:  1986       Impact factor: 4.914

8.  Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain.

Authors:  R B Rothman; V Bykov; B R de Costa; A E Jacobson; K C Rice; L S Brady
Journal:  Peptides       Date:  1990 Mar-Apr       Impact factor: 3.750

9.  Inflammation of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue.

Authors:  A H Hassan; A Ableitner; C Stein; A Herz
Journal:  Neuroscience       Date:  1993-07       Impact factor: 3.590

10.  Kappa 2 opioid receptors inhibit NMDA receptor-mediated synaptic currents in guinea pig CA3 pyramidal cells.

Authors:  R M Caudle; C Chavkin; R Dubner
Journal:  J Neurosci       Date:  1994-09       Impact factor: 6.167

View more
  25 in total

Review 1.  Kappa opioid antagonists: past successes and future prospects.

Authors:  Matthew D Metcalf; Andrew Coop
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

2.  Sex differences in the potency of kappa opioids and mixed-action opioids administered systemically and at the site of inflammation against capsaicin-induced hyperalgesia in rats.

Authors:  Lisa M Lomas; Andrew C Barrett; Jolan M Terner; Donald T Lysle; Mitchell J Picker
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

Review 3.  The mechanism of μ-opioid receptor (MOR)-TRPV1 crosstalk in TRPV1 activation involves morphine anti-nociception, tolerance and dependence.

Authors:  Yanju Bao; Yebo Gao; Liping Yang; Xiangying Kong; Jing Yu; Wei Hou; Baojin Hua
Journal:  Channels (Austin)       Date:  2015-07-15       Impact factor: 2.581

4.  A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates.

Authors:  Huiping Ding; Norikazu Kiguchi; Dennis Yasuda; Pankaj R Daga; Willma E Polgar; James J Lu; Paul W Czoty; Shiroh Kishioka; Nurulain T Zaveri; Mei-Chuan Ko
Journal:  Sci Transl Med       Date:  2018-08-29       Impact factor: 17.956

5.  Effects of peripheral κ opioid receptor activation on inflammatory mechanical hyperalgesia in male and female rats.

Authors:  Q-Schick Auh; Jin Y Ro
Journal:  Neurosci Lett       Date:  2012-07-20       Impact factor: 3.046

6.  Supraspinal actions of nociceptin/orphanin FQ, morphine and substance P in regulating pain and itch in non-human primates.

Authors:  H Ding; K Hayashida; T Suto; D D Sukhtankar; M Kimura; V Mendenhall; M C Ko
Journal:  Br J Pharmacol       Date:  2015-04-24       Impact factor: 8.739

7.  Antinociceptive, reinforcing, and pruritic effects of the G-protein signalling-biased mu opioid receptor agonist PZM21 in non-human primates.

Authors:  Huiping Ding; Norikazu Kiguchi; David A Perrey; Thuy Nguyen; Paul W Czoty; Fang-Chi Hsu; Yanan Zhang; Mei-Chuan Ko
Journal:  Br J Anaesth       Date:  2020-08-17       Impact factor: 9.166

Review 8.  The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability.

Authors:  Ann P Lin; Mei-Chuan Ko
Journal:  ACS Chem Neurosci       Date:  2012-11-06       Impact factor: 4.418

9.  Ultra-long antagonism of kappa opioid agonist-induced diuresis by intracisternal nor-binaltorphimine in monkeys.

Authors:  M C H Ko; K J Willmont; H Lee; G S Flory; J H Woods
Journal:  Brain Res       Date:  2003-08-22       Impact factor: 3.252

Review 10.  Natural products as tools for neuroscience: discovery and development of novel agents to treat drug abuse.

Authors:  Thomas E Prisinzano
Journal:  J Nat Prod       Date:  2009-03-27       Impact factor: 4.050

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.